Food and Drug Administration (FDA) has approved semaglutide (marketed as Wegovy) and Tirzepatide (marketed as Zepbound) specifically for chronic weight management in adults with obesity or overweight individuals with at least one weight-related comorbidity, such as high blood pressure, type 2 diabetes, or high cholesterol
In addition, mitochondria are also the primary producers of intracellular reactive oxygen species (ROS), most of which originate from the mitochondrial respiratory chain [55]
In contrast to dopamine, glutamate and NMDA receptors are widely distributed throughout the brain, leading to a concept of whole brain dysfunction that involves not only the prefrontal and limbic brain regions but also nontraditional regions, such as the auditory and visual cortices
The SeekPeptides platform provides detailed reviews of major GLP-1 providers, helping members compare options with accurate, regularly updated information rather than outdated blog posts from affiliate marketers
Regarding weight loss, the FDA has approved these drugs for people whose body mass index (BMI) is greater than 30 kg/m2, or they have a BMI that is greater than 27 and have a weight-related health problem, such as high blood pressure, sleep apnea, or pre-diabetes
Severe or concerning symptoms warrant medical attention and discontinuation of use